BSE: 544312
HAMPS BIO LIMITED
Operates in two businesses: pharmaceutical trading and freeze-dried food products, including fruits, vegetables, herbs and ready-to-eat foods. Standalone revenue for FY26 was ₹851.65 lakhs, up about 27.7% year-on-year from ₹666.87 lakhs in FY25, with the company stating growth came from both segments. In March 2026 it completed the ₹2.04 crore cash acquisition of HSDL Innovative Private Limited, a freeze-drying food business with FY25 turnover of around ₹1.87 crore, making it a wholly-owned subsidiary. IPO proceeds of ₹622.20 lakhs were fully utilised during the year on plant and machinery, brand visibility and general corporate purposes, lifting property, plant and equipment to ₹391.29 lakhs by end of H1 FY26 from ₹248.18 lakhs at March 2025. Despite revenue growth, the company reported a standalone loss after tax of ₹61.86 lakhs in FY26 versus a profit of ₹40.39 lakhs in FY25, with operating cash flow negative at ₹286.32 lakhs due to working capital pressures from expansion. AR · MarketPing reader · 2026-08-03
Revenue streams, as the annual report describes them. Pharmaceutical trading, Freeze-dried products (FMCG). Small, early-stage FMCG company in a heavy capex build-out phase, with a related freeze-drying subsidiary acquisition and currently loss-making.
Exhibit 1: Financial summary, FY26–FY26 (all audited; no estimate years)
| ₹ crore · consolidated | FY26 |
|---|---|
| Revenue | 8 |
| EBITDA (ex other income) | — |
| margin % | — |
| Owners' profit | — |
| EPS, as reported (₹) | 0.85 |
| ROE % · ROCE % | — · (3.7) |
| Debt / equity (x) | — |
| Cash from operations | (1) |
| Capex | (5) |
Exhibit 2: Quarterly performance, last 1 quarters
| ₹ crore | Q4 FY26 |
|---|---|
| Revenue | 4 |
| Profit before tax | (1) |
| Net profit | — |
| EPS (₹) | 0.62 |
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| LT FOODS LIMITED | 13,579 | 21.2 | 3.00 | 11.6 | 13.8 | 16.0 | 18.7 | 11.5 |
| KRBL LIMITED | 8,108 | 10.7 | 1.40 | 8.4 | 11.2 | 14.7 | 8.8 | 24.9 |
| GUJARAT AMBUJA EXPORTS LT | 6,628 | 15.9 | 2.01 | 12.4 | 9.2 | 11.7 | 4.0 | 17.0 |
| KAVERI SEED CO. LTD. | 3,503 | 14.2 | 2.00 | 9.4 | 16.9 | 17.0 | 6.1 | 40.1 |
| TRUALT BIOENERGY LIMITED | 3,301 | 23.5 | 2.09 | 12.9 | 6.1 | 4.8 | — | 23.5 |
| INDRAYANI BIOTECH LTD. | 2,984 | 22.4 | 29.23 | 218.8 | 1.9 | 0.2 | 45.6 | 8.2 |
| AMIR CHAND JAG KUM (E) L | 2,249 | 21.5 | 2.43 | 13.1 | 11.2 | 14.8 | — | 9.5 |
| GRM OVERSEAS LIMITED | 1,823 | 13.9 | 3.01 | 17.1 | 12.3 | 16.5 | 17.2 | 8.4 |
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 41.1 | 12.3 | 48 of 53 | 10% |
| ROCE | (5.7) | 4.1 | 55 of 67 | 18% |
| Market cap | 22 | 66 | 50 of 69 | 28% |
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 14 Oct 2026 · RTA certifies no share rematerialisation requests in Q2 FY27 | compliance | minimal | — | — |
| 26 Sept 2026 · Trading window closed for H1FY26 results declaration | compliance | minimal | — | — |
| 11 Sept 2026 · Hamps Bio 19th AGM: All 3 resolutions passed with 100% approval | board shareholder meetings | low | — | — |
| 9 Sept 2026 · Board approves pay hikes for CMD, WTD, CFO and Director | management changes | medium | — | — |
| 9 Sept 2026 · 19th AGM of Hamps Bio Limited held on Sept 9, 2026 | board shareholder meetings | low | — | — |
| 17 Aug 2026 · HAMPS BIO FY26 Annual Report; PAT swings to Rs 65.49 lakh loss vs Rs 29.77 lakh profit | results | high | — | — |
| 17 Aug 2026 · Hamps Bio 19th AGM on Sep 9 2026, office shift and director re-appointment on agenda | board shareholder meetings | low | — | — |
| 14 Jul 2026 · RTA certificate filed under SEBI Reg 74(5) for quarter ended June 2026 | compliance | minimal | — | — |
| 6 Jul 2026 · Hamps Bio lists KMPs authorised to determine materiality under Reg 30(5) | compliance | minimal | — | — |
| 6 Jul 2026 · Hamps Bio appoints new Company Secretary after Komal Jain resigns | management changes | medium | — | — |
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.